Molecular Templates - MTEM Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MTEM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTEM, but not buy additional shares or sell existing shares.
View MTEM analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month target prices for Molecular Templates' stock. Their MTEM share price forecasts range from $1.00 to $9.00. On average, they predict the company's stock price to reach $3.83 in the next twelve months. This suggests a possible upside of 607.6% from the stock's current price.
View analysts price targets for MTEM or view top-rated stocks among Wall Street analysts.

Molecular Templates' stock was trading at $3.92 at the beginning of 2022. Since then, MTEM stock has decreased by 86.2% and is now trading at $0.5417.
View the best growth stocks for 2022 here.

Molecular Templates saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 429,100 shares, a decline of 19.6% from the October 31st total of 533,500 shares. Based on an average daily trading volume, of 105,500 shares, the days-to-cover ratio is presently 4.1 days. Approximately 1.0% of the shares of the company are short sold.
View Molecular Templates' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our MTEM earnings forecast.

Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.16. The biotechnology company had revenue of $2.38 million for the quarter, compared to analyst estimates of $15.69 million. Molecular Templates had a negative net margin of 231.40% and a negative trailing twelve-month return on equity of 226.71%.

Shares of Molecular Templates reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Molecular Templates' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.11%), Renaissance Technologies LLC (1.03%), Kingsbury Capital Investment Advisors LLC (0.53%), Two Sigma Advisers LP (0.45%) and Two Sigma Investments LP (0.39%). Insiders that own company stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Sean Mclennan, Shv Management Services, Llc and Target N V Biotech.
View institutional ownership trends.

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MTEM stock can currently be purchased for approximately $0.54.

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $30.53 million and generates $38.70 million in revenue each year. The biotechnology company earns $-83,010,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

The company employs 261 workers across the globe.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.